Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -0.32% | 90.40 | 1.3% | $812.42m | |
| AMGN | Amgen Inc. | -0.03% | 186.92 | 1.2% | $635.34m | |
| GILD | Gilead Sciences, Inc. | 0.33% | 66.98 | 0.9% | $508.19m | |
| BIIB | Biogen Inc. | 0.65% | 335.16 | 1.3% | $445.14m | |
| ILMN | Illumina, Inc. | -0.01% | 302.24 | 3.5% | $320.02m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.45% | 422.51 | 2.6% | $304.29m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.52% | 187.84 | 1.9% | $269.00m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.71% | 129.84 | 2.0% | $236.61m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.22% | 140.57 | 15.4% | $155.25m | |
| A | Agilent Technologies, Inc. | 1.28% | 78.51 | 1.6% | $145.08m | |
| EXAS | Exact Sciences Corporation | -2.27% | 83.63 | 25.3% | $129.45m | |
| INCY | Incyte Corporation | -0.40% | 83.74 | 2.5% | $115.31m | |
| ARRY | Array BioPharma Inc. | 0.30% | 23.17 | 8.2% | $109.81m | |
| EXEL | Exelixis, Inc. | -0.52% | 21.24 | 6.4% | $84.04m | |
| NBIX | Neurocrine Biosciences, Inc. | -1.89% | 79.36 | 5.1% | $80.57m |
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.